JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Protagonist Therapeutics (PTGX) and maintained a price target of $42.
March 11, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics maintains a 'Market Outperform' rating and a $42 price target from JMP Securities.
The reiteration of a 'Market Outperform' rating and the maintenance of a $42 price target by a reputable analyst like Jonathan Wolleben from JMP Securities could instill confidence among investors and potentially lead to a positive short-term price movement for PTGX.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100